Dr. Maky Zanganeh has led many industry transformations ranging from minimally invasive surgical robotics, to a patient-friendly small molecule drug for blood cancer patients. She is known by her colleagues as a leader who has a proven track record of bringing unmistakable intensity and clarity to companies who have transformed healthcare for the betterment of humankind. She firmly believes in the concept “take responsibility and the ability will follow.”

Maky is currently the Co-Chief Executive Officer and President, as well as a member of the board at Summit Therapeutics—a company focusing on the development and commercialization of physician and patient-friendly oncology therapies.

Prior to that, Dr Zanganeh, as Chief Operating Officer at Pharmacyclics (a patient-friendly oncology company), led a struggling biotech company to a multimillion-dollar collaboration and license deal for ibrutinib with Janssen Biotech Inc. in 2011 and, the subsequent sale of the company for $21 billion dollars in 2015 to AbbVie Inc. The deal with Janssen Biotech received the award of the “Best Biotech Transaction” in 2011. Under her leadership in 2015, Pharmacyclics was also awarded the prestigious Prix Galien for “Best Pharmaceutical Agent.” This award is the biomedical industry’s highest accolade and recognizes outstanding achievements in the development of new therapies.